Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Sevelda

Showing results (81-90 of 148) with videos related to

Pageof 15
Sort By:
Obstetrics and Gynecology|August 1, 1995
Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancerF Nagele, E Petru, M Medl, et al.
International Journal of Cancer|November 11, 1992
Breast cancer and timing of surgery during menstrual cycle. A 5-year analysis of 385 pre-menopausal womenM F Gnant, M Seifert, R Jakesz, et al.
Anticancer Research|February 19, 2002
Does long-term application of granulocyte colony-stimulating factor adversely influence overall survival in patients with ovarian cancer? A clinical studyC Peters-Engl, M Medl, U Denison, et al.
Gynakologisch-Geburtshilfliche Rundschau|January 1, 1993
[High-dose epirubicin in combination with high-dose ifosfamide plus granulocyte colony stimulating factor in patients with advanced platin-pretreated ovarian cancer. Phase I-II study]E Küffer, B Fazeny, P Speiser, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 1, 1992
Goserelin a GnRH-analogue as third-line therapy of refractory epithelial ovarian cancerP. Sevelda, N. Vavra, R. Fitz, et al.
Geburtshilfe Und Frauenheilkunde|March 1, 1992
[Prognostic factors of radically operated stage Ib cervix cancer]N Vavra, H Kucera, W Eppel, et al.
Geburtshilfe Und Frauenheilkunde|May 1, 1994
[The value of the "vascular invasion" factor for prognosis of breast cancer]C Kurz, A Obermair, F Nagele, et al.
Gynecologic Oncology|June 1, 1997
Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter studyCh Kurz, Ch Marth, G Windbichler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1991
Clonogenic growth in vitro: an independent biologic prognostic factor in ovarian carcinomaC Dittrich, E Dittrich, P Sevelda, et al.
Acta Obstetricia Et Gynecologica Scandinavica|April 1, 1993
Prognostic factors related to recurrent endometrial carcinoma following initial surgeryN Vavra, U Denison, H Kucera, et al.
Pageof 15

Showing results (81-90 of 148) with videos related to

Sort By:
Pageof 15
Obstetrics and Gynecology|August 1, 1995
Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancerF Nagele, E Petru, M Medl, et al.
International Journal of Cancer|November 11, 1992
Breast cancer and timing of surgery during menstrual cycle. A 5-year analysis of 385 pre-menopausal womenM F Gnant, M Seifert, R Jakesz, et al.
Anticancer Research|February 19, 2002
Does long-term application of granulocyte colony-stimulating factor adversely influence overall survival in patients with ovarian cancer? A clinical studyC Peters-Engl, M Medl, U Denison, et al.
Gynakologisch-Geburtshilfliche Rundschau|January 1, 1993
[High-dose epirubicin in combination with high-dose ifosfamide plus granulocyte colony stimulating factor in patients with advanced platin-pretreated ovarian cancer. Phase I-II study]E Küffer, B Fazeny, P Speiser, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 1, 1992
Goserelin a GnRH-analogue as third-line therapy of refractory epithelial ovarian cancerP. Sevelda, N. Vavra, R. Fitz, et al.
Geburtshilfe Und Frauenheilkunde|March 1, 1992
[Prognostic factors of radically operated stage Ib cervix cancer]N Vavra, H Kucera, W Eppel, et al.
Geburtshilfe Und Frauenheilkunde|May 1, 1994
[The value of the "vascular invasion" factor for prognosis of breast cancer]C Kurz, A Obermair, F Nagele, et al.
Gynecologic Oncology|June 1, 1997
Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter studyCh Kurz, Ch Marth, G Windbichler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1991
Clonogenic growth in vitro: an independent biologic prognostic factor in ovarian carcinomaC Dittrich, E Dittrich, P Sevelda, et al.
Acta Obstetricia Et Gynecologica Scandinavica|April 1, 1993
Prognostic factors related to recurrent endometrial carcinoma following initial surgeryN Vavra, U Denison, H Kucera, et al.
Pageof 15